Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
暂无分享,去创建一个
L. Jeng | M. Kudo | P. Philip | Jianming Xu | P. Johnson | Joong-Won Park | Chih-Hung Hsu | Y. Chao | S. Paik | R. Poon | A. Cheng | T. Decaens | J. Heo | J. Raoul | Ligong Lu | W. Tak | S. Qin | T. Hu | K. Han | Lunan Yan | R. Ezzeddine | E. Boucher | A. Sobhonslidsuk | I. Walters | D. Komov | David Liu | J. Robles-Aviña | Tsung‐Hui Hu
[1] M. Kudo,et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Rudin,et al. Brivanib (B) in Advanced Ovarian Cancer (OC): Subset Results of a Phase 2 Randomized Discontinuation Trial (RDT) , 2012 .
[3] Li-xi Yang,et al. Improved chemotherapy for hepatocellular carcinoma. , 2012, Anticancer research.
[4] Lihong V Wang,et al. A Novel Monoclonal Antibody to Fibroblast Growth Factor 2 Effectively Inhibits Growth of Hepatocellular Carcinoma Xenografts , 2012, Molecular Cancer Therapeutics.
[5] L. Roberts,et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. , 2012, Journal of hepatology.
[6] E. Paci,et al. Does an organised screening programme reduce the inequalities in breast cancer survival? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] R. Finn,et al. Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma , 2011, Clinical Cancer Research.
[8] Y. Rolland,et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma , 2012, Cancer.
[9] V. Mazzaferro,et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .
[10] Riccardo Lencioni,et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.
[11] M. Ratain. Flushing oral oncology drugs down the toilet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W. Hayes,et al. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy , 2011, British Journal of Cancer.
[13] D. Hanahan,et al. Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition , 2011, Clinical Cancer Research.
[14] M. Kudo,et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Rudin,et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C. Rudin,et al. Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Jemal,et al. Global Cancer Statistics , 2011 .
[18] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[19] J. Fargnoli,et al. The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases , 2010, Molecular Cancer Therapeutics.
[20] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[21] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[22] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[23] P. Pollock,et al. Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.
[24] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[25] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[26] J. Fargnoli,et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) , 2008, Journal of medicinal chemistry.
[27] Oriol Casanovas,et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.
[28] P. Dell’Era,et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.
[29] C. Dickson,et al. Fibroblast growth factor signaling in tumorigenesis. , 2005, Cytokine & growth factor reviews.
[30] Y. Shiratori,et al. Altered expression of vascular endothelial growth factor, fibroblast growth factor‐2 and endostatin in patients with hepatocellular carcinoma , 2005, Journal of gastroenterology and hepatology.
[31] S. Fan,et al. Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. , 2001, American journal of surgery.
[32] N. Nagasue,et al. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] 幸子 小笠原. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines , 1997 .
[35] S. Arii,et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor , 1996, Hepatology.
[36] E. S. Pearson,et al. THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .